- Neurology Home
- Center for Neurological Health
- Residency Information
- Fellowship Information
- Clerkship Information
- Internet Resources
Professor of Neurology
University of Florida, Gainesville, Florida 1982-1987
University of Florida College of Medicine, Gainesville, Florida 1982-1988
Sioux Falls V.A. Medical Center, Sioux Falls, South Dakota 1988-1989
University of Michigan, Ann Arbor, Michigan 1989-1992
Research Associate, Howard Hughes Medical Institute, University of Michigan 1992-94
Lecturer in Movement Disorders: University of Michigan 1992-1994
Research Scientist: Ann Arbor VA Medical Center 1994-1998
Assistant Professor: University of Michigan 1994-1998
Assistant Professor: Medical University of Ohio 1998-2009
Professor: University of Toledo (formerly Medical University of Ohio, 2009-present
American Board of Psychiatry and Neurology, 1994
American Academy of Neurology
New York Academy of Science
Society for Neuroscience
Dean's Award for Teaching Excellence 2003
Golden Apple Teaching Award 2003-2007, 2010, 2011
Awarded Humanism in Medicine - MUO Class of 2003, 2002
Named in list of America's Best Doctors, 2001-2012
Teaching Scholar, Medical University of Ohio 2000-01
Pfizer Scholar 1995-97
AdHoc Reviewer for:
Journal of Clinical Investigation 1997
Neurology Network Commentary 1997
Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: A prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun;18(5):488-93.
Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012 Apr 17;78(16):1229-36.
Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012 Mar;71(3):370-84.
Little, KY, Elmer, LW, Zhong, H, Scheys JO, Zhang, L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol. Pharmacol. 2002; 61:436-445.
Pankratz, N, Nichols, WC, Uniacke, SK, Halter, C, Rudolph A, Shults, C, Conneally, PM, Foroud, T, and the Parkinson Study Group. Genome screen to identify susceptibility genes for Parkinson Disease in a sample without parkin mutations. Am. J. Hum. Genet. 2002; 71:124-135.
Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud T, and the Parkinson Study Group. Linkage stratification and mutation analysis at the parkin locus identifies mutation positive Parkinson's disease families. J. Med. Genet. 2002; 39:489-492.
Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW,Penney JB, Tanner C, Kieburtz K, Rudolph A and the Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl andtocopherol antioxidative therapy of parkinsonism trial.Ann Neurol. 2002 May;51(5):604-12.
Shoulson, I and the Parkinson Study Group. A randomized controlled trial of remacemide for motor fluctuations in Parkinson’s disease. Neurology 2001; 56:455-462.
Parkinson Study Group. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for Parkinson’s disease. Neurology 2000; 54:1583-1588.
Shoulson I and the Parkinson Study Group. DATATOP: A decade of neuroprotective inquiry. Ann Neurol. 1998;44(Suppl 1):S160-S166.
Elmer L, Chaná P, Borgohain R, Surmann E, Bauer L, Whitesides J, and Nicholas A. An International Study to Investigate Rotigotine Dose Response (2-8 mg/24 h) on "Off" Time in Patients With Advanced Stage Parkinson's Disease. Poster and Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology, April 21-28, 2012, New Orleans, LA, USA
Elmer L, Chaná P, Borgohain R, Surmann E, Bauer L, Whitesides J, and Nicholas A. A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Access Rotigotine Transdermal System Dose Response in Subjects with Advanced-stage Parkinson's Disease (PD). 16th International Congress of Parkinson's Disease and Movement Disorders (MDS) June 17-21 2012; Dublin, Ireland
Elmer LW, Hauser RA, Parkinson's Disease [PD]/ PD Dementia in Lynn DJ, Newton H, Rae-Grant A. The 5-Minute Neurology Consult. Philadelphia: Lippincott, Williams and Wilkins, 2012.
Menezes K, Elmer LW, Progressive Supranuclear Palsy in Lynn DJ, Newton H, Rae-Grant A. The 5-Minute Neurology Consult. Philadelphia: Lippincott, Williams and Wilkins, 2012.
Nicholas-Bublick S, Elmer LW, Multiple system Atrophy in Lynn DJ, Newton H, Rae-Grant A. The 5-Minute Neurology Consult. Philadelphia: Lippincott, Williams and Wilkins, 2012.
Scott ME, Elmer LW, Dementia with Lewy Bodies in Lynn DJ, Newton H, Rae-Grant A. The 5-Minute Neurology Consult. Philadelphia: Lippincott, Williams and Wilkins, 2012.
Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC and the Parkinson Study Group. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson Disease. Neurology, in press.
Carson R. Reider, PhD, Cheryl A. Halter, MS, Peter F. Castelluccio, MS, David Oakes, PhD, William C. Nichols, PhD, Tatiana Foroud, PhD, and the Parkinson Study Group. Reliability of reported age at onset for Parkinson's disease, Movement Disorders, in press.